Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease

被引:81
作者
Zhou, Yi [1 ]
Bartels, Doug J. [1 ]
Hanzelka, Brian L. [1 ]
Muh, Ute [1 ]
Wei, Yunyi [1 ]
Chu, Hui-May [1 ]
Tigges, Ann M. [1 ]
Brennan, Debra L. [1 ]
Rao, B. Govinda [1 ]
Swenson, Lora [1 ]
Kwong, Ann D. [1 ]
Lin, Chao [1 ]
机构
[1] Vertex Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
D O I
10.1128/AAC.00863-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In patients chronically infected with hepatitis C virus (HCV) strains of genotype 1, rapid and dramatic antiviral activity has been observed with telaprevir (VX-950), a highly selective and potent inhibitor of the HCV NS3-4A serine protease. HCV variants with substitutions in the NS3 protease domain were observed in some patients during telaprevir dosing. In this study, purified protease domain proteins and reconstituted HCV subgenomic replicons were used for phenotypic characterization of many of these substitutions. V36A/M or T54A substitutions conferred less than eightfold resistance to telaprevir. Variants with double substitutions at Val(36) plus Thr(54) had similar to 20-fold resistance to telaprevir, and variants with double substitutions at Val(36) plus Arg(155) or Ala(156) had > 40-fold resistance to telaprevir. An X-ray structure of the HCV strain H protease domain containing the V36M substitution in a cocomplex with an NS4A cofactor peptide was solved at a 2.4-angstrom resolution. Except for the side chain of Met(36), the V36M variant structure is identical to that of the wild-type apoenzyme. The in vitro replication capacity of most variants was significantly lower than that of the wild-type replicon in cells, which is consistent with the impaired in vivo fitness estimated from telaprevir-dosed patients. Finally, the sensitivity of these replicon variants to alpha interferon or ribavirin remained unchanged compared to that of the wild-type.
引用
收藏
页码:110 / 120
页数:11
相关论文
共 54 条
[1]   Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[2]   Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication [J].
Blight, KJ ;
McKeating, JA ;
Rice, CM .
JOURNAL OF VIROLOGY, 2002, 76 (24) :13001-13014
[3]  
Blight KJ, 1998, ANTIVIR THER, V3, P71
[4]  
Carroll SS, 2006, HEPATOLOGY, V44, p535A
[5]   Treatment of chronic hepatitis C: A systematic review [J].
Chander, G ;
Sulkowski, MS ;
Jenckes, MW ;
Torbenson, MS ;
Herlong, HF ;
Bass, EB ;
Gebo, KA .
HEPATOLOGY, 2002, 36 (05) :S135-S144
[6]  
Chen CM, 2006, HEPATOLOGY, V44, p342A
[7]   Telaprevir (VX 950)-resistant variants exhibit reduced replication capacity compared to wild-type HCV in vivo and in vitro [J].
Chu, H-M. ;
Zhou, Y. ;
Bartels, D. J. ;
Khunvichai, A. ;
Rao, B. G. ;
Kwong, A. D. ;
Lin, C. .
JOURNAL OF HEPATOLOGY, 2007, 46 :S230-S231
[8]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[9]   CHARACTERIZATION OF THE HEPATITIS-C VIRUS-ENCODED SERINE PROTEINASE - DETERMINATION OF PROTEINASE-DEPENDENT POLYPROTEIN CLEAVAGE SITES [J].
GRAKOUI, A ;
MCCOURT, DW ;
WYCHOWSKI, C ;
FEINSTONE, SM ;
RICE, CM .
JOURNAL OF VIROLOGY, 1993, 67 (05) :2832-2843
[10]   EXPRESSION AND IDENTIFICATION OF HEPATITIS C VIRUS POLYPROTEIN CLEAVAGE PRODUCTS [J].
GRAKOUI, A ;
WYCHOWSKI, C ;
LIN, C ;
FEINSTONE, SM ;
RICE, CM .
JOURNAL OF VIROLOGY, 1993, 67 (03) :1385-1395